BALTIMORE—2022 was an exciting year in the field of vasculitis, not least of all because the ACR and EULAR released classification criteria for several forms. This development came just one year after the release of ACR/Vasculitis Foundation (VF) guidelines on the management of a number of vasculitides. With so much new information to be absorbed,…
Jason Liebowitz, MD, is a rheumatologist with Skylands Medical Group in Rockaway, N.J. He completed his undergraduate studies at Johns Hopkins University, Baltimore, and was inducted into Phi Beta Kappa. He attended Johns Hopkins University School of Medicine and completed his internal medicine residency at Johns Hopkins Bayview Medical Center, where he also served as a chief resident. He completed his rheumatology fellowship at Johns Hopkins University and was nominated for the 2019 Distinguished Fellow Award from the American College of Rheumatology. His research has been published in JAMA Internal Medicine, The Journal of Rheumatology, Arthritis Care and Research, The American Journal of Medicine and Medical Humanities. He is a co-editor of the textbook, Clinical Innovation in Rheumatology: Past, Present, and Future, published in 2022. He greatly enjoys teaching trainees and caring for patients, which he considers a tremendous honor and privilege, and he is grateful to be able to cover medical conferences and contribute articles to The Rheumatologist.
Articles by Jason Liebowitz, MD
What’s New in RA Research?
Dr. Aletaha discussed several studies of interventions in pre-RA, including SAVE, STIVEA, PROMPT, PRAIRI, TREAT EARLIER and STOP-RA.
All That Is Old—& New: Treatment Implications for Rheumatoid Arthritis
EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…
Concerning the Back: Updates in AS & nr-axSpA
During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.
Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri
At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.
Criteria, Guidelines & Medications: Updates in the World of Vasculitis
The 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of Rheumatic Diseases Symposium session titled, Updates on Vasculitis provided an overview of the latest information on vasculitis diagnosis and treatment.
Infertility 101: What Every Rheumatologist Should Know
Infertility is a frequently encountered issue in medicine, seen in about 9% of men and about 11% of women of reproductive age in the U.S.1 Many rheumatologists may not be aware of the prevalence of infertility and the implications this issue may have on the care of their patients. Here, Anat Chemerinski, MD, instructor in…
What’s Holding Back Biomarker Innovation, & How Can We Solve It?
Think about it. Most rheumatology labs are stuck in the 1960s. Translational biomarker research looks excellent on paper and in theory. However, many barriers exist from the bench to the bedside. This article highlights this problem for the rheumatology community and proposes practical solutions. Case in Point For an example, let’s examine systemic lupus erythematosus…
Break Barriers: Engaging Diverse Participants in Clinical Trials for Patients with Lupus
Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.
The Importance of Health Literacy in Clinical Care
EULAR 2023—It is not enough to practice medicine by the book; rather, communication with patients and understanding their goals for patients are vital to high-quality care. At EULAR 2023, the session titled The Promise of Health Literacy in Clinical Care provided a treasure trove of insights for many clinicians. Definitions & Actions The first speaker…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 16
- Next Page »